utomilumab (PF-05082566) Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

utomilumab (PF-05082566) / Pfizer

NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting

Europe, Canada, Japan, US, RoW

Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600

Pfizer

Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors

09/26

AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Mar 2019 - Dec 2019 : From trial for cancer (unspecified)

Active, not recruiting

100

Vinorelbine, Trastuzumab, Avelumab, Utomilumab

Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University

Breast Cancer

05/23

05/25

InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting

150

Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy

Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences

Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma

06/25

JAVELIN Medley, NCT02554812 / 2015-002552-27: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

	Jan 2024 - Dec 2024: From JAVELIN Medley trial in combination with utomilumab for NSCLC, melanoma and SCCHN
	JAVELIN Medley trial of Bavencio + PF-04518600 + utomilumab in advanced malignancies
	Jan 2018 - Jan 2018: JAVELIN Medley trial of Bavencio + PF-04518600 + utomilumab in advanced malignancies
	Combination study with PF-05082566 for NSCLC
	Sep 2015 - Sep 2015: Combination study with PF-05082566 for NSCLC

Terminated

1/2

409

Europe, Canada, Japan, US, RoW

Avelumab, MSB0010718C, Utomilumab, PF-05082566, PF-04518600, PD 0360324, CMP-001

Pfizer

Advanced Cancer

03/23

NCT03318900: T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Completed

1/2

Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CD8-Positive T-Lymphocyte, CD8 Cell, CD8 Lymphocyte, CD8 Lymphocytes, CD8+ T Cell, CD8+ T Lymphocyte, CD8+ T Lymphocytes, CD8+ T-Lymphocyte, CD8-Positive Lymphocyte, CD8-Positive Lymphocytes, CD8-Positive T-Lymphocytes, T8 Cell, T8 Cells, T8 Lymphocyte, T8 Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma

12/23

NCI-2018-01118, NCT03217747: Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients with Advanced Malignancies

Active, not recruiting

1/2

173

Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Ivuxolimab, Anti-OX40 Agonist Monoclonal Antibody PF-04518600, PF-04518600, PF-8600, PF04518600, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Refractory Malignant Solid Neoplasm, Stage IV Prostate Cancer AJCC V8, Stage IVA Prostate Cancer AJCC V8, Stage IVB Prostate Cancer AJCC V8

09/25

NCT03636503: RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

Active, not recruiting

Rituximab, Utomilumab, Avelumab, PF04518600

Dana-Farber Cancer Institute, Pfizer

Follicular Lymphoma

07/21

10/24

NCT03440567: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Active, not recruiting

Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous Hematopoietic Cell Transplantation, autologous stem cell transplantation, Stem Cell Transplantation, Autologous, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide Phosphate, Etopophos, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566

City of Hope Medical Center, National Cancer Institute (NCI)

Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

12/24

NCT03290937: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients with Metastatic Colorectal Cancer

Active, not recruiting

Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Pharmacodynamic Study, PHARMACODYNAMIC, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566

M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC V8, Stage IVA Colorectal Cancer AJCC V8, Stage IVB Colorectal Cancer AJCC V8, Stage IVC Colorectal Cancer AJCC V8

12/26



	Diseases Companies Products Productz Mechanisms of Action Sites